BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at Cannabis Investor Conference

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be a featured company in the upcoming Cannabis Industry Virtual Investor Conference, slated for Sept. 8–9, 2021; INM’s presentation is scheduled for Sept. 8 at 1:30 p.m. ET. The two-day conference is an exclusive opportunity for cannabis company leaders to share the vision and mission of their companies and meet with potential investors.The conference is hosted by Virtual Investor Conferences (“VIC”) in partnership with KCSA Strategic Communications. VIC is part of OTC Market Group’s suite of investor relations services and is designed to be an interactive forum for publicly traded companies to meet and present directly with investors. The event replicates the look and feel of onsite investor conferences and combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network. “Our 15th virtual conference with the OTC Markets has generated significant interest from both investors and cannabis companies to where we again have extended the conference to two days,” said KCSA Strategic Communications managing director Phil Carlson in the press release. “We look forward to having some of the prominent global players in the cannabis industry present their story to the investment community.”

To register for the event, visit https://ibn.fm/0HHBZ

To view the full press release, visit https://ibn.fm/Og5N3

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (“CBN”), in diseases with high unmet medical need. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork